Skip to main content
SpringerPlus
Fig. 1 | SpringerPlus

Fig. 1

From: Characteristics of safety information obtained from postmarketing observational studies for re-examination in Japan

Fig. 1

Scatter plot of the adverse reaction rate in clinical studies for NDA (ARR-NDA) and the adverse reaction rate in PMO studies for re-examination (ARR-PMO) (176 drug products, 206 sets). Vertical axis ARR-NDA adverse reaction rate in clinical studies for NDA. Horizontal axis ARR-PMO adverse reaction rate in postmarketing observational studies for re-examination

Back to article page